Compare Colgate-Palmolive Company (CL) vs GSK plc (GSK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Colgate-Palmolive Company vs GSK plc — how do they compare? Colgate-Palmolive Company trades at $91.52 (market cap $73.59B), while GSK plc trades at $49.88 (market cap $102.60B). The key difference: GSK plc is the larger of the two by market cap, and GSK plc pays the higher dividend (3.57%). Which is the better fit depends on your goals.
| CL | GSK | |
|---|---|---|
Market Cap | $73.59B | $102.60B |
Sector | Consumer Staples | Health |
52-Week High | $99.14 | $61.18 |
52-Week Low | $74.98 | $38.22 |
Enterprise Value | $80.07B | $123.04B |
Dividend Yield | 2.3% | 3.57% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Colgate-Palmolive (CL) trades at $93.15, down 0.13% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported Q2 2026 EPS of $0.99, beating estimates, with 4.9% sales growth driven by emerging markets. However, North American weakness persists, and valuation ratios like P/E of 36.34 and P/B of 311.81 appear elevated. Cash flow remains positive, and a dividend of $0.53 is scheduled for August 2026.
Outlook is mixed: strong brand presence and dividend sustainability support the stock, but high valuation and domestic challenges pose risks. Analyst consensus price target is $99.10, implying modest upside, with 42% buy ratings. Key risks include competitive pressures and margin compression from inflation.
GSK trades at $52.16, down 1.51% today, with a bullish technical signal supported by moving averages. The company reported strong Q2 2026 earnings of $1.36 per share, beating estimates, and announced a $2.52 billion cost-saving plan to accelerate drug development. Revenue growth remains steady, with 2025 revenue at $32.67 billion and net income of $5.72 billion, though profit margins have fluctuated in recent years.
Outlook is positive with continued earnings beats and strategic investments, but risks include competitive pressures and regulatory uncertainties. Analyst sentiment is mixed with 31% buy ratings, 55% hold, and 14% sell, reflecting cautious optimism amid execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Colgate-Palmolive Company
Since its founding in 1806, Colgate-Palmolive has grown to become a leading global consumer product company. In addition to its namesake oral care line, the firm manufactures shampoos, shower gels, deodorants, and home care products that are sold in over 200 countries (international sales account for about 70% of its consolidated total, including approximately 45% from emerging regions). It also owns specialty pet food maker Hill's, which sells its products through veterinarians and specialty pet retailers.
Read more on CL →About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →
